Created with Proto Axiom
Onyx Axiom
A next‑generation topical antifungal for onychomycosis — combining the safety of topical therapy with efficacy approaching oral drugs, via a novel lyotropic liquid crystal drug‑delivery system.
Therapeutics Topical antifungal · Lyotropic liquid crystal drug delivery
Onyx Axiom founders.
The science · The story
How the company was formed, and what it is building.
Onyx Axiom is developing a next‑generation topical treatment for onychomycosis (toenail fungus) using a novel lyotropic liquid crystal drug‑delivery system to enhance the efficacy of terbinafine while avoiding the systemic side effects of oral antifungals.
Proto Axiom formed Onyx Axiom in 2025, licensing the underlying IP into Australia under an exclusive global licence.
A Phase IIb clinical trial is currently under way.
- Founded
- 2025
- Origin
- Melbourne
- Sector
- Therapeutics
- Modality
- Topical antifungal · Lyotropic liquid crystal drug delivery
Leadership
Founders and key team.
Dr. Paul Gavin
Chief Executive Officer · Commercial Founder
Melbourne
Lawrence Gozlan
Director · Commercial Founder
Proto Axiom Strategic Advisor
Anthony Liveris
Director
Proto Axiom (founding investor)
Programme status
Where the programme is now, and what comes next.
- Now
- Phase IIb clinical trial of topical terbinafine for onychomycosis.
In the press
Recent news.
[ Press mentions to be added as they publish. ]